

Amy Jo Chien

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8607147/publications.pdf>

Version: 2024-02-01

22
papers

1,815
citations

586496

16
h-index

759306

22
g-index

24
all docs

24
docs citations

24
times ranked

2869
citing authors

#	ARTICLE	IF	CITATIONS
1	Adaptive Randomization of Veliparibâ€“Carboplatin Treatment in Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 23-34.	13.9	467
2	Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. <i>Cancer</i> , 2012, 118, 1710-1717.	2.0	430
3	Adaptive Randomization of Neratinib in Early Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 11-22.	13.9	301
4	Association of Event-Free and Distant Recurrenceâ€“Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1355.	3.4	119
5	Cellular Mechanisms of Resistance to Anthracyclines and Taxanes in Cancer: Intrinsic and Acquired. <i>Seminars in Oncology</i> , 2008, 35, S1-S14.	0.8	75
6	MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive and/or Hormone Receptorâ€“Negative Breast Cancers in the I-SPY 2 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1059-1069.	0.8	69
7	Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer. <i>Human Reproduction</i> , 2017, 32, 2123-2129.	0.4	59
8	Fertility preservation with ovarian stimulation and time to treatment in women with stage IIâ€“III breast cancer receiving neoadjuvant therapy. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 151-159.	1.1	47
9	Fertility preservation before breast cancer treatment appears unlikely to affect diseaseâ€“free survival at a median followâ€“up of 43Âmonths after fertilityâ€“preservation consultation. <i>Cancer</i> , 2020, 126, 487-495.	2.0	43
10	Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1654.	3.4	42
11	A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 521-530.	1.1	27
12	Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 524-524.	0.8	27
13	Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial. <i>Npj Breast Cancer</i> , 2020, 6, 48.	2.3	21
14	A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. <i>Npj Breast Cancer</i> , 2019, 5, 17.	2.3	19
15	Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 173-181.	1.1	17
16	Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy. <i>Cancers</i> , 2020, 12, 1511.	1.7	9
17	Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAMoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial. <i>Journal of Assisted Reproduction and Genetics</i> , 2021, 38, 2455-2463.	1.2	8
18	The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study. <i>Npj Breast Cancer</i> , 2021, 7, 156.	2.3	8

#	ARTICLE	IF	CITATIONS
19	Emerging immunotherapeutic strategies for the treatment of breast cancer. Breast Cancer Research and Treatment, 2022, 191, 243-255.	1.1	4
20	Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials.. Journal of Clinical Oncology, 2021, 39, 1092-1092.	0.8	3
21	Invasive Lobular Carcinoma of the Breast: Ongoing Trials, Challenges, and Future Directions. Current Breast Cancer Reports, 2021, 13, 164-170.	0.5	1
22	Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorshipâ€™Associated Distress: Survey Study. JMIR Cancer, 2022, 8, e31756.	0.9	0